Elhaik Goldman Shirin, Dotan Shahar, Talias Amir, Lilo Amit, Azriel Shalhevet, Malka Itay, Portnoi Maxim, Ohayon Ariel, Kafka Daniel, Ellis Ronald, Elkabets Moshe, Porgador Angel, Levin Ditza, Azhari Rosa, Swiatlo Edwin, Ling Eduard, Feldman Galia, Tal Michael, Dagan Ron, Mizrachi Nebenzahl Yaffa
Pediatric Infectious Disease Unit, Soroka University Medical Center, Beer‑Sheva 84100, Israel.
NasVax/Protea Vaccine Technologies Ltd., Kiryat Weizmann, Science Park, Ness Ziona 74140, Israel.
Int J Mol Med. 2016 Apr;37(4):1127-38. doi: 10.3892/ijmm.2016.2512. Epub 2016 Mar 1.
Streptococcus pneumoniae (S. pneumoniae) is a major pathogen worldwide. The currently available polysaccharide-based vaccines significantly reduce morbidity and mortality. However, the inherent disadvantages of the currently available polysaccharide-based vaccines have motivated the search for other bacterial immunogens capable of eliciting a protective immune response against S. pneumoniae. Fructose-1,6-bisphosphate aldolase (FBA) is a glycolytic enzyme, which was found to localize to the bacterial surface, where it functions as an adhesin. Previously, immunizing mice with recombinant FBA (rFBA) in the presence of alum elicited a protective immune response against a lethal challenge with S. pneumoniae. Thus, the aim of the present study was to determine the cytokine responses that are indicative of protective immunity following immunization with rFBA. The protective effects against pneumococcal challenge in mice immunized with rFBA with complete Freund's adjuvant (CFA) in the initial immunization and with incomplete Freund's adjuvant (IFA) in booster immunizations surpassed the protective effects observed following immunization with either rFBA + alum or pVACfba. CD4+ T-cells obtained from the rFBA/CFA/IFA/IFA-immunized mice co-cultured with rFBA-pulsed antigen-presenting cells (APCs), exhibited a significantly greater proliferative ability than CD4+ T-cells obtained from the adjuvant-immunized mice co-cultured with rFBA‑pulsed APCs. The levels of the Th1-type cytokines, interferon (IFN)-γ, interleukin (IL)-2, tumor necrosis factor (TNF)-α and IL-12, the Th2-type cytokines, IL-4, IL-5 and IL-10, and the Th17-type cytokine, IL-17A, significantly increased within 72 h of the initiation of co-culture with CD4+ T-cells obtained from the rFBA‑immunized mice, in comparison with the co-cultures with CD4+ T-cells obtained from the adjuvant-immunized mice. Immunizing mice with rFBA resulted in an IgG1/IgG2 ratio of 41, indicating a Th2 response with substantial Th1 involvement. In addition, rabbit and mouse anti-rFBA antisera significantly protected the mice against a lethal S. pneumoniae challenge in comparison with preimmune sera. Our results emphasize the mixed involvement of the Th1, Th2 and Th17 arms of the immune system in response to immunization with pneumococcal rFBA, a potential vaccine candidate.
肺炎链球菌是全球范围内的主要病原体。目前可用的基于多糖的疫苗显著降低了发病率和死亡率。然而,目前可用的基于多糖的疫苗的固有缺点促使人们寻找其他能够引发针对肺炎链球菌的保护性免疫反应的细菌免疫原。果糖-1,6-二磷酸醛缩酶(FBA)是一种糖酵解酶,被发现定位于细菌表面,并在那里作为一种黏附素发挥作用。此前,在明矾存在的情况下用重组FBA(rFBA)免疫小鼠,可引发针对肺炎链球菌致死性攻击的保护性免疫反应。因此,本研究的目的是确定在用rFBA免疫后指示保护性免疫的细胞因子反应。在用完全弗氏佐剂(CFA)进行初次免疫并用不完全弗氏佐剂(IFA)进行加强免疫的情况下,用rFBA免疫的小鼠对肺炎球菌攻击的保护作用超过了用rFBA + 明矾或pVACfba免疫后观察到的保护作用。从与rFBA脉冲抗原呈递细胞(APC)共培养的rFBA/CFA/IFA/IFA免疫小鼠中获得的CD4 + T细胞,与从与rFBA脉冲APC共培养的佐剂免疫小鼠中获得的CD4 + T细胞相比,表现出显著更高的增殖能力。与从佐剂免疫小鼠中获得的CD4 + T细胞共培养相比,在用从rFBA免疫小鼠中获得的CD4 + T细胞开始共培养的72小时内,Th1型细胞因子干扰素(IFN)-γ、白细胞介素(IL)-2、肿瘤坏死因子(TNF)-α和IL-12、Th2型细胞因子IL-4、IL-5和IL-10以及Th17型细胞因子IL-17A的水平显著增加。用rFBA免疫小鼠导致IgG1/IgG2比值为41,表明存在Th2反应且有大量Th1参与。此外,与免疫前血清相比,兔和小鼠抗rFBA抗血清显著保护小鼠免受肺炎链球菌致死性攻击。我们的结果强调了免疫系统的Th1、Th2和Th17分支在对肺炎球菌rFBA(一种潜在的疫苗候选物)免疫反应中的混合参与。